Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 19/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018076 | 0.85 | CCR4 (0.58) | CCR4CCR5FFAR4SLCO1B1ADORA2A | |
| SCHEMBL13186539 | 0.80 | CCR4 (0.55) | CCR4CCR5FFAR4SLCO1B1ADORA2A | |
| SCHEMBL358297 | 0.80 | CCR4 (0.55) | CCR4CCR5FFAR4SLCO1B1ADORA2A | |
| SCHEMBL22678941 | 0.78 | CCR4 (0.66) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL27571 | 0.77 | CCR4 (0.62) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL18803 | 0.75 | CCR4 (0.54) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL30084 | 0.73 | CCR4 (0.53) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL12473980 | 0.72 | CCR4 (0.48) | CCR4CCR5FFAR4SLCO1B1 | |
| SCHEMBL185508 | 0.69 | CCR4 (0.60) | CCR4 | |
| SCHEMBL18001 | 0.69 | CCR4 (0.56) | CCR4CCR5FFAR4SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | CCR4 1/4885CCR5 8/4885FFAR4 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.